Boston Sci Slammed After Cyberattack Hamstrings Sales
Boston Scientific is experiencing ongoing operational delays and financial losses following an August cyberattack that disabled order processing, shipping, and global manufacturing. The company missed its financial guidance, with estimated revenue losses of up to 7%. CEO Mike Mahoney stated recovery is taking longer than expected. The disruptions have impacted the delivery of cardiac devices to hospitals.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Boston Scientific reported the cyberattack's impact in a Form 8-K filing to the U.S. Securities and Exchange Commission on October 7, 2026.
- ✓ The cyberattack caused operational delays and financial losses for the company.
What changed
No new developments were reported on the cyberattack's impact on Boston Scientific's operations.
Live updates
-
Boston Sci Faces Continued Delays After Cyberattack
Boston Scientific is experiencing ongoing operational delays and financial losses following an August cyberattack that disabled order processing, shipping, and global manufacturing. The company missed its financial guidance, with estimated revenue losses of up to 7%. CEO Mike Mahoney stated recovery is taking longer than expected. The disruptions have impacted the delivery of cardiac devices to hospitals.
Why it matters
The cyberattack has significant implications for Boston Scientific, a major medical device manufacturer. The company's ability to deliver critical cardiac devices to hospitals has been compromised, potentially impacting patient care. The financial losses and operational delays have also raised concerns among investors and analysts.
What is confirmed
- Boston Scientific reported the cyberattack's impact in a Form 8-K filing to the U.S. Securities and Exchange Commission on October 7, 2026.
- The cyberattack caused operational delays and financial losses for the company.
What to watch next
- Boston Scientific's financial report for the quarter
- Update on the company's recovery progress
- Any further announcements from CEO Mike Mahoney
confidence 90%Sources used for this update (4)
- www.bostonglobe.com — MI5 chief says Iran is targeting military sites - The Boston Globe | New England news, weather and sports
- meetings.skift.com — Cybercriminals Invented an Entire Conference — and Used a ...
- www.boston.com — Visting Boston: Things to do, food and drink, and more
- www.newbostonpost.com — 50 Best Things to Do in Boston: The Ultimate 2026 Guide
-
Boston Scientific Struggles With Recovery From August Cyberattack
Boston Scientific continues to face operational delays and financial losses following a cyberattack in August. The breach disabled order processing, shipping, and global manufacturing, which stopped the delivery of cardiac devices to hospitals. CEO Mike Mahoney stated that recovery is taking longer than the company expected. These disruptions caused the firm to miss its financial guidance, with analysts estimating a potential revenue loss of up to seven percent. The company reported these developments in a Form 8-K filing to the U.S. Securities and Exchange Commission on October 7, 2026.
Why it matters
The company provides critical medical hardware for cardiac care. Disruptions in the supply chain for these devices can impact hospital operations and patient care. This event highlights the vulnerability of medical manufacturing to digital infrastructure failures.
What is confirmed
- Boston Scientific filed a Form 8-K with the U.S. Securities and Exchange Commission on October 7, 2026.
- A cyberattack in August disabled global manufacturing, shipping, and order processing for the company.
- CEO Mike Mahoney confirmed that operational recovery is taking longer than anticipated.
Still unconfirmed
- Analysts project a revenue hit of up to seven percent.
- The company missed its financial guidance due to the attack.
What to watch next
- Updated financial reports confirming the exact revenue loss
- Public statements on the restoration of cardiac device deliveries to hospitals
- Details regarding the origin or nature of the August cyberattack
confidence 100%Sources used for this update (6)
- www.boston.com — Boston.com: Local breaking news, sports, weather, and things to do
- www.meetboston.com — Meet Boston | Your Official Guide to Boston
- en.wikipedia.org — Boston - Wikipedia
- www.boston.gov — Homepage | Boston.gov
- www.boston.com — Boston news: Local and national breaking news, crime, and...
- en.wikipedia.org — History of Boston - Wikipedia
-
Boston Scientific Files SEC Update Amid Cyberattack Recovery
Boston Scientific submitted a Form 8-K to the U.S. Securities and Exchange Commission on October 7, 2026, marking its latest regulatory filing as the company attempts to recover from a disruptive August cyberattack. The attack previously crippled global manufacturing, shipping, and order processing, halting critical cardiac device deliveries to hospitals. CEO Mike Mahoney confirmed that operational recovery is taking longer than anticipated, leading analysts to project a revenue hit of up to seven percent and causing the company to miss financial guidance.
Why it matters
Regulatory disclosures to the Securities and Exchange Commission serve as the primary source of verified financial data for investors tracking the fallout from the cyberattack. These filings track essential metrics including annual revenue, debt levels, and material business events that reveal the depth of operational disruption. The October filing arrives while the firm works to restore order processing and manufacturing systems after the August security breach.
What is confirmed
- Boston Scientific submitted a Form 8-K current report to the U.S. Securities and Exchange Commission on October 7, 2026.
- Boston Scientific has submitted over 940 documents to the U.S. Securities and Exchange Commission since 2017.
What to watch next
- Additional disclosures in upcoming SEC filings regarding third-quarter financial impacts
- Official updates from Boston Scientific on full-year financial guidance adjustments
confidence 100%Sources used for this update (2)
- stockanalysis.com — Boston Scientific (BSX) Revenue 2005-2026 - Stock Analysis
- www.marketbeat.com — Boston Scientific (BSX) 10K Form and Latest SEC Filings 2026
-
Boston Scientific Hit by Cyberattack Disrupting Global Shipments
Boston Scientific faces severe financial and operational fallout following an August cyberattack that disabled global manufacturing, shipping, and order processing. The disruption halted cardiac device shipments to hospitals, resulting in facility closures and likely lost orders that will cause the company to miss third-quarter and full-year financial guidance. CEO Mike Mahoney confirmed the ongoing recovery is taking longer than expected. Stock shares dropped six percent as analysts project up to a seven percent revenue hit for the third quarter.
Why it matters
Global medical device manufacturers operate on tight distribution networks where delivery delays directly impact patient care and hospital operations. Supply chain interruptions of this scale threaten corporate earnings and erode investor confidence, forcing firms to scramble for operational recovery. Boston Scientific now contends with both immediate inventory backlogs and longer-term fiscal adjustments.
What is confirmed
- Boston Scientific shares dropped six percent after the company disclosed that an August cyberattack will materially impact third-quarter and full-year sales and earnings.
- CEO Mike Mahoney confirmed the company likely lost orders due to facility closures.
- The incident halted cardiac device shipments to hospitals and disabled global manufacturing, shipping, and order processing.
Still unconfirmed
- Analysts model up to a seven percent revenue hit for the third quarter.
What to watch next
- Official third-quarter financial results and revised earnings guidance from Boston Scientific.
- Updates on the full restoration of global manufacturing and shipping capabilities.
confidence 100%Sources used for this update (2)
- thearabianpost.com — Boston Scientific cyberattack disrupts global device shipments
- www.marketscreener.com — Boston Scientific Corporation: Official Announcements - Stock ...
-
Boston Scientific Shares Fall Following August Cyberattack
Boston Scientific shares dropped six percent after the company disclosed that an August cyberattack will materially impact third-quarter and full-year sales and earnings. The incident halted cardiac device shipments to hospitals and disabled global manufacturing, shipping, and order processing. CEO Mike Mahoney confirmed the company likely lost orders due to facility closures. Recovery efforts are taking longer than expected, leading the firm to expect it will miss financial guidance. Analysts model up to a seven percent revenue hit for the third quarter.
Why it matters
The August cyberattack has disrupted core operations at Boston Scientific, directly affecting hospitals awaiting cardiac device shipments. Financial analysts previously estimated the sales hit at $300 million alongside a reduction in earnings per share. This operational disruption forces a reevaluation of the company's financial trajectory for both the third quarter and the full year.
What is confirmed
- Boston Scientific disclosed that an August cyberattack will materially impact third-quarter and full-year sales and earnings.
- The cyberattack halted cardiac device shipments to hospitals and recovery is taking longer than expected.
- Boston Scientific stock dropped six percent following the cyberattack.
Still unconfirmed
- Analysts model up to a seven percent third-quarter revenue hit for Boston Scientific.
What to watch next
- Updates on the timeline for full operational recovery of global manufacturing and shipping.
- Official company revisions to third-quarter and full-year financial guidance.
confidence 90%Sources used for this update (5)
- www.investors.com — Earnings | Investor's Business Daily
- research.investors.com — Boston Scientific Stock Quote: BSX Stock News, Quotes ...
- www.upwind.io — Cyberkicks Boston 2026 - Upwind
- shattered.io — Boston Scientific Hack Cuts Q3 Revenue Up to 7%
- dailysecurityreview.com — Boston Scientific Cyberattack Damages Q3 and Full-Year ...
-
Boston Scientific Recovery Continues After Cyberattack Disrupts Production
Boston Scientific is working to recover operations after a cyberattack disabled global manufacturing, shipping, and order processing. CEO Mike Mahoney confirmed the company likely lost orders due to facility closures. The firm will probably miss its 2026 third-quarter and full-year financial guidance for net sales and adjusted earnings per share. Wells Fargo analyst Larry Biegelsen estimates the hit at $300 million in sales and $0.13 per share in earnings, leading to a price target reduction from $50 to $48.
Why it matters
The incident demonstrates how digital attacks can halt physical production without damaging equipment. This vulnerability affects the broader medical technology sector.
What is confirmed
- Boston Scientific missed its financial guidance for net sales and adjusted earnings per share for the third quarter and full year of 2026.
- CEO Mike Mahoney stated the company likely lost orders during facility closures.
Still unconfirmed
- A Salesforce breach via SalesLoft and Drift integrations impacted over 700 firms.
What to watch next
- Official third-quarter financial results from Boston Scientific
- Confirmation of the specific attack vector used to disable Boston Scientific facilities
confidence 90%Sources used for this update (3)
- dailysecurityreview.com — Cloudflare Confirms Salesforce Breach in Growing Supply Chain ...
- finance.technews.tw — 駭客沒有炸工廠，卻讓工廠停擺：Boston Scientific 網攻揭開製造業最...
- pharmaphorum.com — AstraZeneca reportedly hit by serious cyberattack
-
Boston Scientific Faces Financial Fallout After Cyberattack
Boston Scientific faces severe financial fallout following a recent cyberattack that disrupted global manufacturing, order processing, and shipping operations. Chief Executive Officer Mike Mahoney stated that the company likely lost orders during facility closures. Wells Fargo analyst Larry Biegelsen estimated the financial damage at roughly $300 million in sales and about $0.13 per share in earnings. Consequently, Wells Fargo lowered its price target on Boston Scientific to $48 from $50. The medical device manufacturer announced it is unlikely to meet its financial guidance for net sales and adjusted earnings per share for the third quarter and the full year of 2026.
Why it matters
Cyberattacks on major medical device manufacturers carry significant operational risks because prolonged downtime directly halts the production and distribution of critical healthcare equipment. Financial analysts closely track these security breaches to assess immediate losses and long-term adjustments in corporate valuation. The situation highlights the vulnerability of global supply chains to digital disruptions and the direct link between network security and quarterly earnings.
What is confirmed
- A cyberattack on Boston Scientific disrupted global manufacturing, order processing, and shipping.
- CEO Mike Mahoney stated that the company likely lost orders during plant and distribution center closures.
- Boston Scientific disclosed it is unlikely to meet its third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share.
- Wells Fargo analyst Larry Biegelsen estimated the incident could cost roughly $300 million in sales and about $0.13 per share in earnings.
- Wells Fargo lowered its price target on Boston Scientific to $48 from $50.
What to watch next
- Boston Scientific financial disclosures for the third quarter of 2026
- Further analyst revisions to the company stock price target and earnings estimates
confidence 100%Sources used for this update (2)
- cyberixsafe.com — Boston Scientific Cyberattack: The Real Cost | Cyberix
- www.insidermonkey.com — Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a ...
-
Boston Scientific Operations Restored After Cyberattack Disrupts Guidance
Boston Scientific operations are fully restored following an August 25 cyberattack that disrupted manufacturing, order processing, and shipping. CEO Mike Mahoney stated that the company likely lost orders during plant and distribution center closures. The medical device firm disclosed it is unlikely to meet its third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Wells Fargo analyst Larry Biegelsen estimated the incident could cost the company roughly $300 million in sales and about $0.13 per share in earnings, prompting the firm to lower its price target on Boston Scientific to $48 from $50.
Why it matters
The August 25 security breach hit Boston Scientific on-premises IT, paralyzing critical manufacturing and distribution infrastructure. This operational halt triggered an immediate financial setback, forcing the medical device corporation to revise its full-year financial outlook downward. Stock trading for the company dropped 2.3 percent in early trading on September 8, 2026, as markets reacted to the disrupted guidance.
What is confirmed
- Boston Scientific disclosed that an August 25 cyberattack disrupted manufacturing, order processing, and shipping.
- The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share.
- Boston Scientific stock fell 2.3 percent in early trading on September 8, 2026.
- CEO Mike Mahoney stated that the company likely lost orders while plants and distribution centers were shut down.
Still unconfirmed
- Wells Fargo estimated the cybersecurity incident could impact third-quarter results by roughly $300 million in sales and about $0.13 per share in earnings.
What to watch next
- The upcoming October 28 financial update from Boston Scientific.
- Official third-quarter financial results detailing the exact monetary impact of the cyberattack.
confidence 100%Sources used for this update (9)
- finance.yahoo.com — Boston Scientific fully restores operations after cyberattack
- finance.yahoo.com — Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.
- news.bostonscientific.com — Update on recent cybersecurity incident
- dailysecurityreview.com — Boston Scientific Cyberattack Disrupts Manufacturing and ...
- business-news-today.com — Boston Scientific’s cyberattack knocks its 2026 outlook off ...
- www.supplychain.nhs.uk — Supplier Update Boston Scientific Cyber Attack
- dailysecurityreview.com — Masimo Cyberattack Disrupts Operations Amid $350M Audio Brand ...
- www.marketbeat.com — BSX News Today | Why did Boston Scientific stock go down ...
- finance.yahoo.com — Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a ...
-
Boston Scientific Misses 2026 Forecasts Following Cyberattack
Boston Scientific will likely miss its 2026 sales and profit guidance after a cyberattack disrupted operations. The company indicated it is unlikely to meet its earnings forecasts, leading to a drop in stock price. The attack hampered sales capabilities, forcing the medical device firm to revise its financial expectations for the year. Multiple financial news outlets confirm the company's inability to reach previously stated targets due to the security breach.
Why it matters
Financial guidance serves as a benchmark for investor expectations and company health. A failure to meet these forecasts often triggers immediate market volatility. This incident highlights the vulnerability of medical technology supply chains to digital disruption.
What is confirmed
- Boston Scientific is unlikely to meet its 2026 sales and profit forecasts.
- A cyberattack caused the company to miss its earnings guidance.
- The company's stock price fell following the announcement.
What to watch next
- Disclosure of the specific nature or origin of the cyberattack
- Revised 2026 financial guidance figures
- Details on the extent of sales disruptions
confidence 100%Sources used for this update (5)
- wsj.com — Boston Scientific Won’t Meet Guidance Due to Cyberattack
- Reuters — Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
- Bloomberg.com — Boston Scientific Unlikely to Meet Forecasts After Cyber Attack
- Barron's — Boston Scientific ‘Unlikely to Meet’ Earnings Guidance After Cyberattack. Stock Falls.
- Investor's Business Daily — Boston Sci Slammed After Cyberattack Hamstrings Sales
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community